FGFR3 is overexpressed Waldenström macroglobulinemia and its inhibition by dovitinib induces apoptosis and overcomes stroma-induced proliferation

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4389-4399

  Azab, Abdel Kareem ^a   Azab, Feda ^a   Quang, Phong ^a   Maiso, Patricia ^a   Sacco, Antonio ^a   Ngo, Hai T ^a   Liu, Yang ^a   Zhang, Yong ^a   Morgan, Brittany L ^a   Roccaro, Aldo M ^a   Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 3; DEXAMETHASONE; DOVITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MELPHALAN; ANTINEOPLASTIC AGENT; FGFR3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ADHESION; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACELLULAR SIGNALING; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL; TUMOR GROWTH; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; DISEASE COURSE; DRUG ANTAGONISM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE MUTANT; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, SCID; PROTEIN KINASE INHIBITORS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; STROMAL CELLS; TUMOR MICROENVIRONMENT; WALDENSTROM MACROGLOBULINEMIA;

EID: 79960312724     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2772     Document Type: Article

References (22)

1. Olsen SK, Ibrahimi OA, Raucci A, Zhang F, Eliseenkova AV, Yayon A, et al. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc Natl Acad Sci U S A 2004;101:935-40. (Pubitemid 38160562)
2. Reimers K, Antoine M, Zapatka M, Blecken V, Dickson C, Kiefer P. NoBP, a nuclear fibroblast growth factor 3 binding protein, is cell cycle regulated and promotes cell growth. Mol Cell Biol 2001;21:4996-5007. (Pubitemid 32656397)
3. Sonvilla G, Allerstorfer S, Heinzle C, Stattner S, Karner J, Klimpfinger M, et al. Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. Br J Cancer 2010;102:1145-56.
4. Miyake M, Sugano K, Sugino H, Imai K, Matsumoto E, Maeda K, et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. Cancer Sci 2010;101:250-8.
5. Henson BJ, Gollin SM. Overexpression of KLF13 and FGFR3 in oral cancer cells. Cytogenet Genome Res 2010;128:192-8.
6. Soverini S, Terragna C, Testoni N, Ruggeri D, Tosi P, Zamagni E, et al. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. Haematologica 2002;87:1036-40. (Pubitemid 35192214)
7. Vatsveen TK, Brenne AT, Dai HY, Waage A, Sundan A, Borset M. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14). Eur J Haematol 2009; 83:471-6.
8. Keats JJ, Reiman T, Belch AR, Pilarski LM. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 2006;47:2289-300. (Pubitemid 44768421)
9. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-5. (Pubitemid 36506291)
10. Ghobrial IM, Leleu X, Azab AK, Runnels J, Jia X, Ngo H, et al. Novel therapeutic agents in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:84-6.
11. Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood 2007;109: 5096-103.
12. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, et al. CHIR- 258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005;105:2941-8. (Pubitemid 40446289)
13. Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005;11:5281-91. (Pubitemid 41003717)
14. Grand FH, Iqbal S, Zhang L, Russell NH, Chase A, Cross NC. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Exp Hematol 2007;35:1723-7. (Pubitemid 47633767)
15. Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005;11:3633-41.
16. Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger- Zimmerli P, et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 2008;14:2075-81. (Pubitemid 351551118)
17. Xin X, Abrams TJ, Hollenbach PW, Rendahl KG, Tang Y, Oei YA, et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res 2006;12:4908-15. (Pubitemid 44338578)
18. Ngo HT, Azab AK, Farag M, Jia X, Melhem MM, Runnels J, et al. Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clin Cancer Res 2009;15: 6035-41.
19. Schop RF, Kuehl WM, Van Wier SA, Ahmann GJ, Price-Troska T, Bailey RJ, et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002;100:2996-3001.
20. Zingone A, Cultraro CM, Shin DM, Bean CM, Morse HC 3rd, Janz S, et al. Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. Leukemia 24:1171-8.
21. Wu JY, Huang L, Xiong J, Cao Y, Sun LS, Liu WL, et al. [Expression of a tumor related gene fgfr3 mRNA in leukemic cells and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008;16: 738-41.
22. Vijay A, Gertz MA. Current treatment options for Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma 2008;8:219-29.